Loading the security overview…
Where the tokens are
First the companies classified under the same themes, most themes in common first; then the ones investors most often look at alongside TEM. A peer with a tokenized version links to its own page, where every issuer that wraps it is listed.
| Company | Shared themes | Market cap | P/E | P/S | EV/EBITDA | ROE | F-Score | Altman zone |
|---|---|---|---|---|---|---|---|---|
| — | $13.89B | — | 9.7 | -114.0 | −57.2% | 3/9 | safe | |
| AI-Powered Analytics & Decision SystemsPrecision Medicine Platforms | $8.01B | 76.2 | 8.1 | 44.3 | 17.8% | 5/9 | safe | |
| AI-Powered Analytics & Decision SystemsHealth IT & Data Infrastructure | $5.53B | 22.1 | 2.5 | 14.7 | 28.9% | 7/9 | safe | |
| AI-Powered Analytics & Decision SystemsPrecision Medicine Platforms | $706.56M | — | — | — | — | 2/9 | distress | |
| AI-Powered Analytics & Decision SystemsHealth IT & Data Infrastructure | $361.15M | — | 0.4 | 10.3 | 96.1% | — | distress | |
| AI-Powered Analytics & Decision Systems | $456.68B | 151.4 | 74.2 | 170.8 | 30.9% | 7/9 | safe | |
| Health IT & Data Infrastructure | $327.8B | 23.2 | 0.7 | 15.0 | 14.3% | 6/9 | safe | |
| AI-Powered Analytics & Decision Systems | $272.46B | 4660.6 | 50.5 | 1258.2 | 1.1% | 3/9 | safe | |
| Precision Medicine Platforms | $244.58B | 110.1 | 10.2 | 48.8 | 16.4% | 8/9 | safe | |
| Precision Medicine Platforms | $241.26B | 34.6 | 5.2 | 24.6 | 13.2% | 6/9 | safe | |
| Precision Medicine Platforms | $148.86B | 37.2 | 5.9 | 22.3 | 7.6% | 6/9 | safe | |
| AI-Powered Analytics & Decision Systems | $120.65B | — | 22.2 | -123.2 | −50.7% | 4/9 | safe | |
| Health IT & Data Infrastructure | $108.97B | 22.3 | 0.3 | 9.9 | 6.1% | 8/9 | distress | |
| AI-Powered Analytics & Decision Systems | $99.27B | 559.0 | 25.0 | 655.9 | 4.1% | 6/9 | safe | |
| AI-Powered Analytics & Decision Systems | $94.14B | 21.4 | 13.8 | 17.4 | 139.4% | 8/9 | safe |
Figures describe Tempus AI shares, not any token. From theme classifications, Massive's related companies and the latest ratios and scores. Ratios are trailing, each as of its own latest filing. Peers are for comparison, not a list of alternatives to buy.